GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Shiller PE Ratio

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Shiller PE Ratio : 54.80 (As of May. 03, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Shiller PE Ratio?

As of today (2024-05-03), Laboratorios Farmaceuticos Rovi's current share price is €82.20. Laboratorios Farmaceuticos Rovi's E10 for the quarter that ended in Dec. 2023 was €1.50. Laboratorios Farmaceuticos Rovi's Shiller PE Ratio for today is 54.80.

The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Shiller PE Ratio or its related term are showing as below:

XMAD:ROVI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 30.06   Med: 48.8   Max: 105.81
Current: 54.95

During the past years, Laboratorios Farmaceuticos Rovi's highest Shiller PE Ratio was 105.81. The lowest was 30.06. And the median was 48.80.

XMAD:ROVI's Shiller PE Ratio is ranked worse than
69.54% of 151 companies
in the Biotechnology industry
Industry Median: 34.81 vs XMAD:ROVI: 54.95

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted earnings per share data for the three months ended in Dec. 2023 was €0.994. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €1.50 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Laboratorios Farmaceuticos Rovi Shiller PE Ratio Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Shiller PE Ratio Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.74 69.67 90.47 30.34 40.24

Laboratorios Farmaceuticos Rovi Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.34 30.07 32.33 36.48 40.24

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Shiller PE Ratio

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Shiller PE Ratio falls into.



Laboratorios Farmaceuticos Rovi Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Laboratorios Farmaceuticos Rovi's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=82.20/1.5
=54.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Laboratorios Farmaceuticos Rovi's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.994/121.2698*121.2698
=0.994

Current CPI (Dec. 2023) = 121.2698.

Laboratorios Farmaceuticos Rovi Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.119 100.139 0.144
201406 0.181 101.081 0.217
201409 0.098 100.441 0.118
201412 0.086 100.251 0.104
201503 0.130 99.474 0.158
201506 0.144 101.138 0.173
201509 0.060 99.559 0.073
201512 0.067 100.268 0.081
201603 0.191 98.638 0.235
201606 0.174 100.333 0.210
201609 0.071 99.737 0.086
201612 0.093 101.842 0.111
201703 0.129 100.896 0.155
201706 0.190 101.848 0.226
201709 0.026 101.524 0.031
201712 0.004 102.975 0.005
201803 0.139 102.122 0.165
201806 0.014 104.165 0.016
201809 0.164 103.818 0.192
201812 0.041 104.193 0.048
201903 0.125 103.488 0.146
201906 0.167 104.612 0.194
201909 0.262 103.905 0.306
201912 0.155 105.015 0.179
202003 0.251 103.469 0.294
202006 0.283 104.254 0.329
202009 0.311 103.521 0.364
202012 0.257 104.456 0.298
202103 0.430 104.857 0.497
202106 0.491 107.102 0.556
202109 0.865 107.669 0.974
202112 0.988 111.298 1.077
202203 0.984 115.153 1.036
202206 0.517 118.044 0.531
202209 0.797 117.221 0.825
202212 1.493 117.650 1.539
202303 0.906 118.948 0.924
202306 0.360 120.278 0.363
202309 0.984 121.343 0.983
202312 0.994 121.270 0.994

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Laboratorios Farmaceuticos Rovi Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.